The Shift From "Less Bad" to Actually Better
A recent perspective piece in Psychiatric Times is drawing renewed attention to a problem that has quietly defined depression care for decades: clinicians and patients alike have often settled for partial improvement rather than pushing toward full remission. The piece, published in April 2026, argues that aggressive, remission-focused treatment is both achievable and necessary — and that balancing side effects with patient priorities should be central to that process, not an afterthought.
For the estimated 30% of people with major depressive disorder who don't respond adequately to two or more antidepressants — the clinical threshold for treatment-resistant depression (TRD) — this framing carries real weight. It's also directly relevant to the growing number of people who are exploring or currently using low-dose ketamine as part of their TRD management.
What the Clinical Guidance Actually Says
The Psychiatric Times piece doesn't introduce new trial data, but rather synthesizes evolving clinical thinking around TRD management strategies. The core argument is that when first- and second-line antidepressants fail, the clinical response should become more systematic and more ambitious — not less. Strategies discussed include augmentation approaches, switching agents, psychotherapy combinations, and interventional options such as esketamine (Spravato) and, by extension, off-label intravenous or oral ketamine protocols.
Importantly, the piece emphasizes individualized goal-setting. Remission — defined broadly as minimal residual symptoms and restored functioning — looks different for every patient, and treatment plans should reflect that. Side effect burden, life circumstances, and what the patient actually values in their recovery all factor in. This is a meaningful departure from the older, more algorithmic "try this, then try that" approach that has frustrated many people living with TRD.
Where Low-Dose Ketamine Fits In
Ketamine's role in TRD has grown considerably over the past several years, and 2026 clinical thinking reflects that maturation. Both IV ketamine infusions and oral/sublingual low-dose formulations are increasingly discussed as legitimate options once standard antidepressants have failed — not as last resorts, but as tools with a distinct mechanism that may work precisely when monoaminergic approaches do not.
Low-dose ketamine operates primarily through NMDA receptor antagonism and downstream BDNF signaling, which means it targets neurobiological pathways that SSRIs, SNRIs, and other conventional agents largely leave untouched. For patients who have cycled through multiple antidepressants without sustained relief, this mechanistic difference is clinically meaningful, not just theoretical.
The Psychiatric Times perspective aligns with this: when the standard toolkit hasn't worked, the answer isn't to keep cycling through similar agents at slightly different doses. It's to reassess the entire treatment strategy, potentially including interventional options like ketamine.
Evidence Strength: What We Know and What We Don't
It's worth being precise about the evidence base here. Esketamine (intranasal Spravato) has FDA approval specifically for TRD, supported by randomized controlled trial data. Off-label oral and IV ketamine have a growing body of observational and open-label evidence, along with a smaller but expanding set of controlled studies. The clinical consensus is cautiously positive — meaningful response rates, rapid onset compared to conventional antidepressants, and a safety profile that is manageable when protocols are followed — but long-term maintenance data remains thinner than most clinicians would prefer.
The remission-focused framing in this piece is a useful lens for ketamine patients specifically. Response (feeling somewhat better) and remission (returning to full functioning with minimal symptoms) are different targets. Ketamine can produce rapid, dramatic response — but sustaining that over months and years typically requires a thoughtful maintenance strategy, whether that's periodic booster doses, integration with therapy, or combination with other treatments.
Key Takeaway for Ketamine Patients
If you're using low-dose ketamine for treatment-resistant depression, the goal should be remission — not just feeling somewhat better than you did on your last antidepressant. Work with your provider to define what remission actually looks like for you, establish clear metrics for tracking progress, and build a maintenance plan before acute response fades. Ketamine's rapid onset can create a misleading sense of resolution; the harder clinical work is sustaining it.
Practical Implications for Dosing and Monitoring
The remission-over-response framework has direct implications for how low-dose ketamine should be approached in practice. A few considerations worth discussing with your prescriber:
- Define your baseline clearly. Use validated tools — PHQ-9, GAD-7, or clinician-administered scales — before starting ketamine and at regular intervals. "Feeling better" is not a sufficient metric when the goal is remission.
- Don't stop at initial response. Some patients experience significant improvement after their first few doses and prematurely taper or discontinue. Discuss with your provider what a full acute course looks like and when to reassess.
- Build a maintenance protocol proactively. The evidence for ketamine's durability varies widely by individual. Monthly maintenance doses, quarterly check-ins, or integration with psychotherapy are all strategies in active clinical use — but the right approach is individualized, not standardized.
- Monitor for dissociation and cardiovascular effects. Low-dose oral ketamine has a more modest side effect profile than IV infusions, but regular monitoring of blood pressure and psychological state remains appropriate, particularly during dose adjustments.
- Communicate side effect burden honestly. The Psychiatric Times piece explicitly flags that patient priorities — including tolerability — should shape treatment decisions. If side effects are affecting your quality of life or adherence, that's clinical information your provider needs.
The broader message from emerging clinical guidance is an encouraging one: treatment-resistant doesn't mean treatment-impossible. For people who have spent years cycling through ineffective antidepressants, the push toward remission-focused, individualized care — with ketamine as one legitimate tool in that process — represents a meaningful shift in how the field approaches this population.
Read the original piece at Psychiatric Times.
Share